Sun Pharma, Ranbaxy Surge Over 5%
Sun Pharmaceutical Industries stock gained more than 6 per cent on Friday, heading towards its biggest single-day gain since April 9.
Credit Suisse says Sun has received a Form 483 from the US Food and Drug Administration (FDA) on a Gujarat facility. FDA's Form 483 is a letter that notifies company of objectionable conditions.
Credit Suisse said the Form 483 given to Sun contained "no data integrity issues". It also said chances of an import alert were "low".
Ranbaxy Laboratories, which is in the process of being acquired by Sun Pharma, was also up 5.5 per cent.
Sun said on September 12 the FDA inspected its plant, but expected "no material impact".
A Sun spokesman did not immediately respond to request for comment.
As of 3:05 p.m., shares in Sun Pharma were trading at Rs 197.65 apiece on the BSE, up 5.41 per cent from the previous close.
Copyright @ Thomson Reuters 2014
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
